These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31101513)

  • 1. Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia.
    Wang Y; Yang X; Song X; Zhao L; Wei J; Wang J; Tian H; Zheng C; Wei M; Wang Q; Guo W; Deng W; Li T; Ma X
    Schizophr Res; 2019 Jul; 209():135-140. PubMed ID: 31101513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia.
    Ghaleiha A; Noorbala AA; Farnaghi F; Hajiazim M; Akhondzadeh S
    J Clin Psychopharmacol; 2010 Dec; 30(6):678-82. PubMed ID: 21105281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.
    Morozova MA; Lepilkina TA; Rupchev GE; Beniashvily AG; Burminskiy DS; Potanin SS; Bondarenko EV; Kazey VI; Lavrovsky Y; Ivachtchenko AV
    CNS Spectr; 2014 Aug; 19(4):316-23. PubMed ID: 23768250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
    Haig GM; Wang D; Zhao J; Othman AA; Bain EE
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial.
    Wang X; Zhao J; Hu Y; Jiao Z; Lu Y; Ding M; Kou Y; Li B; Meng F; Zhao H; Li H; Li W; Yang Y; Lv L
    Psychiatry Res; 2018 Nov; 269():271-277. PubMed ID: 30170285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
    Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
    Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Ning YP; Xiang YT
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):149-158. PubMed ID: 29174529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive Pregnenolone Ameliorates the Cognitive Deficits in Recent-Onset Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Kreinin A; Bawakny N; Ritsner MS
    Clin Schizophr Relat Psychoses; 2017; 10(4):201-210. PubMed ID: 24496044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
    Andersen TH; Bech P; Larsen NE
    Nord J Psychiatry; 2005; 59(3):205-8. PubMed ID: 16195121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Jie Yu Wan on Generalized Anxiety Disorder: A Randomized Clinical Trial.
    Li X; Zheng S; Feng S; Ma R; Jia Y; Zhao A; Wei D; Guo H; Duan N; Ding Y; Chen J; Zhu H; Jia H
    Evid Based Complement Alternat Med; 2022; 2022():9951693. PubMed ID: 35432560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive Memantine Treatment of Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Study.
    Hassanpour F; Zarghami M; Mouodi S; Moosazadeh M; Barzegar F; Bagheri M; Hendouei N
    J Clin Psychopharmacol; 2019; 39(6):634-638. PubMed ID: 31688396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.
    Keefe RSE; Harvey PD; Khan A; Saoud JB; Staner C; Davidson M; Luthringer R
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29873956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.